GlassScriptPhysician profile
Jonathan Besas
NPI 1124400031
$15,193.71
in general payments reported to CMS, 2019-2025
31 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2021: $74.99 · 2022: $445 · 2023: $4,107 · 2024: $8,756 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $2,270 · Travel and Lodging: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $2,270.35 |
| Travel and Lodging | $447.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,938.62 | 2023-2025 | Da Vinci Surgical System |
| Abiomed | $526.74 | 2023-2025 | Impella |
| Novo Nordisk INC | $437.68 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $331.87 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $230.18 | 2022-2025 | Trelegy Ellipta, Nucala |
| Novartis Pharmaceuticals Corporation | $120.56 | 2022-2024 | |
| Allergan, INC. | $116.87 | 2019 | |
| Gilead Sciences, INC. | $114.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.86 | 2022-2025 | Ofev |
| Amarin Pharma, INC. | $107.02 | 2019 | |
| Merck Sharp & Dohme LLC | $101.83 | 2022-2025 | Winrevair, Keytruda, Recarbrio |
| Inspire Medical Systems, INC. | $100.56 | 2023-2025 | Inspire |
| Fresenius USA Marketing, INC. | $100.40 | 2025 | Novalung System |
| Mylan Specialty L.P. | $96.31 | 2021-2024 | Yupelri, Tobi Podhaler |
| United Therapeutics Corporation | $90.51 | 2022-2024 | Tyvaso |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $84.33 | 2019-2022 | |
| Shionogi INC | $72.67 | 2022-2024 | Fetroja |
| Baxter Healthcare | $72.38 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $69.16 | 2024 | |
| Abbvie INC. | $61.86 | 2022-2024 | Teflaro |
| Regeneron Healthcare Solutions, INC. | $49.68 | 2022-2025 | Dupixent |
| Pfizer INC. | $46.62 | 2021-2025 | |
| Amgen INC. | $39.20 | 2023-2024 | Tezspire |
| Potrero Medical, INC. | $33.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.55 | 2022-2024 | Glassia |
| Jazz Pharmaceuticals INC. | $29.84 | 2022 | |
| Covis Pharma Gmbh | $27.29 | 2023 | |
| Ethicon US, LLC | $19.26 | 2022 | |
| Verona Pharma, INC. | $18.02 | 2025 | Ohtuvayre |
| Eurofins Viracor, LLC | $14.69 | 2024 | |
| Body Vision Medical INC. | $3.22 | 2024 | Lungvision |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Besas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.